Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$11.08+0.18 (+1.65%)
Close on Nov 18, 2026Market cap $2.42BP/E –Yield –
Neogen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Neogen's operating income for the twelve months ending Aug 31, 2026 was -$7.38M. For fiscal 2026 it was -$21.60M. The highest annual figure on record is $74.17M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$21.60M | – |
| FY2025 | May 31, 2025 | -$1.06B | -1910.6% |
| FY2024 | May 31, 2024 | $58.60M | +56.2% |
| FY2023 | May 31, 2023 | $37.52M | -36.0% |
| FY2022 | May 31, 2022 | $58.62M | -21.0% |
| FY2021 | May 31, 2021 | $74.17M | +9.8% |
| FY2020 | May 31, 2020 | $67.52M | -0.8% |
| FY2019 | May 31, 2019 | $68.09M | -3.0% |
| FY2018 | May 31, 2018 | $70.19M | +8.1% |
| FY2017 | May 31, 2017 | $64.95M | +15.2% |
| FY2016 | May 31, 2016 | $56.39M | +6.2% |
| FY2015 | May 31, 2015 | $53.12M | +22.4% |
| FY2014 | May 31, 2014 | $43.39M | +6.6% |
| FY2013 | May 31, 2013 | $40.71M | +20.6% |
| FY2012 | May 31, 2012 | $33.74M | -5.8% |
| FY2011 | May 31, 2011 | $35.84M | +33.3% |
| FY2010 | May 31, 2010 | $26.88M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$1.80M | – |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $3.10M | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$3.30M | -161.1% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$5.38M | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | -$16.10M | -813.3% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$611.20M | -4809.9% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $5.40M | -55.1% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$457.48M | -3262.7% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $2.26M | -88.2% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $12.98M | -44.6% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $12.02M | -23.3% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $14.47M | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $19.14M | +215.7% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $23.43M | +29.9% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $15.68M | +145.9% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$7.66M | -161.4% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $6.06M | -72.1% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $18.03M | -11.0% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $6.38M | -59.6% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $12.47M | -35.2% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $21.75M | +15.1% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $20.26M | +1.6% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $15.77M | +20.9% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $19.25M | +5.3% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $18.90M | +16.2% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $19.94M | +6.5% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $13.04M | -10.9% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $18.27M | +0.1% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $16.26M | -1.3% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $18.73M | -5.7% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $14.64M | -8.0% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $18.25M | +1.4% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $16.48M | +0.3% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $19.86M | +4.5% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $15.91M | +10.9% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $18.00M | +6.8% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $16.42M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $19.00M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $14.35M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $16.85M | – |
See a number that looks wrong?